SONN - long - catalyst - low floaterSonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hem
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−24.20 USD
−18.83 M USD
147.81 K USD
645.32 K
About Sonnet BioTherapeutics Holdings, Inc.
Sector
Industry
CEO
Pankaj Mohan
Website
Headquarters
Princeton
Founded
2011
FIGI
BBG000BVZ4N6
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded by Pankaj Mohan and John K. Cini in 2011 and is headquartered in Princeton, NJ.
$SONN A Pillar For Immuno OncologySome drugs address specific illnesses, while others enhance the pharmacokinetic responses of other drugs, which basically means that it assists other drugs. Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN)’s FHAB™ compound does both by causing swelling around tumors which assists in the immune r
SONN 1W test
Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The compan
SONN 15Min Scalpers editiontest
Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The compa
SONN Technical Analysis 🧙Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of SONN is 4.23 USD — it has increased by 0.23% in the past 24 hours. Watch Sonnet BioTherapeutics Holdings, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Sonnet BioTherapeutics Holdings, Inc. stocks are traded under the ticker SONN.
SONN stock has fallen by −25.60% compared to the previous week, the month change is a −17.45% fall, over the last year Sonnet BioTherapeutics Holdings, Inc. has showed a −59.35% decrease.
We've gathered analysts' opinions on Sonnet BioTherapeutics Holdings, Inc. future price: according to them, SONN price has a max estimate of 240.00 USD and a min estimate of 56.00 USD. Watch SONN chart and read a more detailed Sonnet BioTherapeutics Holdings, Inc. stock forecast: see what analysts think of Sonnet BioTherapeutics Holdings, Inc. and suggest that you do with its stocks.
SONN reached its all-time high on Jul 27, 2005 with the price of 9,609,600.00 USD, and its all-time low was 4.14 USD and was reached on Oct 28, 2024. View more price dynamics on SONN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
SONN stock is 5.28% volatile and has beta coefficient of 0.14. Track Sonnet BioTherapeutics Holdings, Inc. stock price on the chart and check out the list of the most volatile stocks — is Sonnet BioTherapeutics Holdings, Inc. there?
Today Sonnet BioTherapeutics Holdings, Inc. has the market capitalization of 2.96 M, it has decreased by −26.88% over the last week.
Yes, you can track Sonnet BioTherapeutics Holdings, Inc. financials in yearly and quarterly reports right on TradingView.
Sonnet BioTherapeutics Holdings, Inc. is going to release the next earnings report on Dec 12, 2024. Keep track of upcoming events with our Earnings Calendar.
SONN earnings for the last quarter are −5.60 USD per share, whereas the estimation was −6.12 USD resulting in a 8.50% surprise. The estimated earnings for the next quarter are −5.04 USD per share. See more details about Sonnet BioTherapeutics Holdings, Inc. earnings.
Sonnet BioTherapeutics Holdings, Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of 28.50 K USD. In the next quarter, revenue is expected to reach 28.00 K USD.
SONN net income for the last quarter is −3.51 M USD, while the quarter before that showed 365.43 K USD of net income which accounts for −1.06 K% change. Track more Sonnet BioTherapeutics Holdings, Inc. financial stats to get the full picture.
No, SONN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has 12.00 employees. See our rating of the largest employees — is Sonnet BioTherapeutics Holdings, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Sonnet BioTherapeutics Holdings, Inc. EBITDA is −12.20 M USD, and current EBITDA margin is −12.47 K%. See more stats in Sonnet BioTherapeutics Holdings, Inc. financial statements.
Like other stocks, SONN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Sonnet BioTherapeutics Holdings, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Sonnet BioTherapeutics Holdings, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Sonnet BioTherapeutics Holdings, Inc. stock shows the sell signal. See more of Sonnet BioTherapeutics Holdings, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.